Table 4 Difference of the antimicrobial susceptibility between HV-positive and- negative of K. pneumoniae
No. (%) of patients susceptible | |||
|---|---|---|---|
Antimicrobial agent | HV-Positive isolates | HV-Negative isolates | P value |
n = 14 | n = 29 | ||
piperacillin | 8 (57.1) | 9 (31.0) | 0.101 |
Cefazolin | 5 (35.7) | 10 (34.4) | 1.000 |
Cefoxitin | 10 (71.4) | 14 (48.3) | 0.152 |
Cefuroxime | 11 (78.6) | 11(37.9) | 0.012* |
Ceftriaxone | 12 (85.7) | 12 (41.4) | 0.006* |
Ceftazidime | 12 (85.7) | 12 (41.4) | 0.006* |
Cefotaxime | 12 (85.7) | 13 (44.8) | 0.011* |
Cefepime | 13 (92.9) | 23 (79.3) | 0.492 |
Imipenem | 14 (100) | 28 (96.6) | 1.000 |
Meropenem | 14 (100) | 28 (96.6) | 1.000 |
Ciprofloxacin | 12 (85.7) | 15 (51.7) | 0.031* |
Levofloxacin | 12 (85.7) | 16 (55.2) | 0.104 |
Gentamicin | 14 (100) | 17(58.6) | 0.013* |
Amikacin | 14 (100) | 18 (62.1) | 0.022* |
Trimethoprim-sulfamethoxazole | 12 (85.7) | 17 (58.6) | 0.013* |
ESBLs | 2 (14.3) | 18 (62.1) | 0.003* |